LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies

Executive Summary

• LIR Life Sciences announced the launch of a controlled comparative animal study to evaluate cell‑penetrating peptide (CPP)‑mediated, needle‑free transdermal delivery of second‑generation GLP/GIP‑based obesity therapies.
• The study will compare topical CPP formulation versus standard subcutaneous injection using a glucose tolerance test in small animals, with results intended to guide further IND‑enabling work.
• LIR also entered into a market‑making services agreement with ICP Securities Inc., effective Jan 13 2026, for an initial four‑month term at a monthly fee of C$7,500 (plus taxes).

Key Details

• Study Design: Controlled comparative in‑vivo study in small animal model; animals receive either topical CPP formulation or subcutaneous injection followed by a standardized glucose challenge.
• Endpoints: Blood glucose levels measured over time; primary focus on stability of glucose profile and overall glucose control relative to injectable benchmark.
• Therapeutic Focus: Second‑generation GLP/GIP‑based incretin therapies for obesity and metabolic conditions (class‑wide assessment, not a single molecule).
• Purpose: Generate functional data to assess feasibility of needle‑free transdermal delivery platform and inform selection of lead candidates for IND‑enabling development.
• CEO Quote: “Demonstrating glucose control from a skin‑applied formulation would validate a tangible therapeutic pathway with the potential to streamline development across multiple GLP/GIP‑based drugs,” – Edward Mills, CEO.
• Market‑Making Agreement:
• Counterparty: ICP Securities Inc., Toronto, ON.
• Services: Automated market making using proprietary ICP Premium™ algorithm in compliance with CSE regulations.
• Fee: C$7,500 per month plus applicable taxes.
• Term: Initial four‑month term starting Jan 13 2026; automatically renews on a monthly basis unless 30‑day notice is given.
• No performance‑based compensation, stock options, or third‑party funding involved.
• Future Outlook: Data from the study expected to help define where needle‑free delivery may match injectable performance and guide further development pathways.

Notable Quotes

• “What matters most about this study is the ability to explore a delivery pathway with potential relevance across a whole class of incretin therapies, rather than focusing on one molecule alone.” – Edward Mills, CEO, LIR Life Sciences.